There’s no therapy developed yet, that can stop cancer cells from moving throughout the body. New research shows that it may be possible to do so, in freezing cancer cells and killing them where they stand.
Researchers have developed a new method for correcting the errors that creep into DNA barcodes, yielding far more accurate results and paving the way for more ambitious medical research in the future.
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. And the animals show no signs that the change in their DNA has had any other impact on their health or wellbeing — yet.
The U.S. Patent and Trademark Office has decided to grant not just one, but two new CRISPR patents to UC Berkeley, home of pioneer Jennifer Doudna, who many consider the creator of the technology.
Computational researchers have developed a computer program which has revealed a previously unknown combination of drugs that may be the answer to triple-negative breast cancer.
When it comes to understanding what makes people tick—and get sick—medical science has long assumed that the bigger the sample of human subjects, the better. New research suggests this big data approach may be wildly off the mark.
The Swiss drugmaker has clearly noticed the genomic profiling group’s ability to personalise cancer care, now that it will take complete ownership of the company.
Digital health devices have become invaluable tools for improving human health. However, could a pill carrying an inbuilt sensor dehumanize patients, reducing them to a digital readout?
Scientists are now genetically engineering monkeys using CRISPR in an attempt to understand how autism affects the brain.
A new project to publish a controversial Cannabis genome to the blockchain may be big news for scientists seeking to head off patent battles and prove the originality of their research.
George Church talks about his disappointment with the Human Genome Project, the blistering price/performance improvements in both DNA synthesis and sequencing, and CRISPR’s strength and weaknesses, in addition to the improvements he hopes to see in its successors.